位置:首页 > 产品库 > Tetrahydropalmatine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tetrahydropalmatine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tetrahydropalmatine图片
CAS NO:2934-97-6

延胡索乙素
DL-Tetrahydropalmatine
Tetrahydropalmatine 可用于缓解疼痛的研究。Tetrahydropalmatine 通过抑制大鼠杏仁核的多巴胺释放来抑制癫痫发作。
生物活性

Tetrahydropalmatine possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release ofdopamineto inhibit an epileptic attack in rats[1].

IC50& Target

Dopamine[1]

体内研究
(In Vivo)

Tetrahydropalmatine (THP), an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects. Picrotoxin treatment alone has a significant effect on the following activity measure: there is an increase in horizontal motion time (HMT), vertical motion time (VMT), clockwise turnings (CT), anticlockwise turning (ACT) and a decrease in freezing time (FT). Tetrahydropalmatine treatment alone causes a decrease in HMT, VMT and total distance traveled (TDT), but an increase in FT. Pretreatment of rats with an i.p. dose of 10 mg/kg or 15 mg/kg of Tetrahydropalmatine significantly attenuates the Picrotoxin-induced enhancement in HMT, VMT, CT, ACT and TDT, as well as reduction in FT. Another 48 rats under urethane anesthesia are randomly divided into six groups, each of eight rats. The s.c. injection of Picrotoxin causes an increase in amygdaloid release of dopamine (DA), while i.p. injection of Tetrahydropalmatine at 10 mg/kg has an insignificant effect on amygdaloid release of DA. Again, the Picrotoxin-induced increase in amygdaloid release of DA is significantly attenuated by pretreatment with Tetrahydropalmatine. The Picrotoxin-induced augmented amygdaloid release of DA is almost completely abolished by pretreatment with Tetrahydropalmatine 30 min before s.c. injection of Picrotoxin[1].

分子量

355.43

性状

Solid

Formula

C21H25NO4

CAS 号

2934-97-6

中文名称

四氢帕马丁;延胡索乙素;DL-四氢帕马丁;DL-延胡索乙素

结构分类
  • Alkaloids
  • Isoquinoline Alkaloids
来源
  • Plants
  • Papaveraceae
  • Corydalis yanhusuoW. T. Wang
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 6.67 mg/mL(18.77 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM2.8135 mL14.0675 mL28.1349 mL
5 mM0.5627 mL2.8135 mL5.6270 mL
10 mM0.2813 mL1.4067 mL2.8135 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 0.67 mg/mL (1.89 mM); Clear solution

    此方案可获得 ≥ 0.67 mg/mL (1.89 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 6.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
*以上所有助溶剂都可在本网站选购。
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024